Nicotinamide (NAM)

DIETARY_SUPPLEMENT4 trials

Sponsors

Société des Produits Nestlé (SPN), Metro International Biotech, LLC, Gates Medical Research Institute, Beth Israel Deaconess Medical Center

Conditions

Acute Kidney InjuryDrug Susceptible Pulmonary TuberculosisHealthyHealthy Adults

Phase 1

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

RecruitingNCT06882096

Metro International Biotech, LLCHealthy Adults

Start: 2025-04-28End: 2027-06-30Target: 32Updated: 2025-05-06

Phase 2

Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

SuspendedNCT07517445

Gates Medical Research InstituteDrug Susceptible Pulmonary Tuberculosis

Start: 2026-04-17End: 2027-06-14Target: 165Updated: 2026-08-10

Unknown Phase

Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults

CompletedNCT05517122

Société des Produits Nestlé (SPN)Healthy

Start: 2022-07-12End: 2022-11-24Updated: 2025-04-24

NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury

Not yet recruitingNCT07739290

Beth Israel Deaconess Medical CenterAcute Kidney Injury

Start: 2026-09-01End: 2029-01-01Target: 20Updated: 2026-07-31

Related Papers

The differential impact of three different NAD<sup>+</sup> boosters on circulatory NAD and microbial metabolism in humans.

2026-01-15